(VIANEWS) - Shares of Arcturus Therapeutics (NASDAQ: ARCT) dropped by a staggering 15.15% in 5 sessions from $22.91 at -15.15, to $19.44 at 12:43 EST on Thursday, after four sequential sessions in a row of losses. NASDAQ is rising 0.35% to $11,951.78, following the last session's downward trend.
Arcturus Therapeutics's last close was $19.59, 37.63% under its 52-week high of $31.41.
About Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $-3.55.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -69.48%.Moving Average
Arcturus Therapeutics's worth is higher than its 50-day moving average of $18.30 and way above its 200-day moving average of $17.49.Growth Estimates Quarters
The company's growth estimates for the current quarter is 11.7% and a drop 21.1% for the next.Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Arcturus Therapeutics's stock is considered to be overbought (>=80).
Revenue Growth
Year-on-year quarterly revenue growth grew by 1254%, now sitting on 40.57M for the twelve trailing months.
More news about Arcturus Therapeutics (ARCT).